SUMMARY The efficacy of treatment with an aldose reductase inhibitor (1,3-dioxo-l H-benz-deisoquinoline-2(3H)-acetic acid, AY-22,284, Alrestatin) on peripheral nerve function in diabetic polyneuropathy was assessed. Thirty patients with long-standing diabetes and slight to moderate neuropathy participated in the double-blind placebo trial. Clinical examination, sensory threshold determinations for vibratory, tactile and thermal stimuli, conduction velocity measurements and studies of automatic function were performed to evaluate the treatment. Significant differences favouring Alrestatin over placebo were found for many of the measured variables, whereas no changes occurred on placebo. The apparent improvement of neuropathy occurred despite persisting hyperglycaemia. The results indicate that aldose reductase inhibitor treatment may be of value in diabetic polyneuropathy, and provide support for the sorbitol pathway hypothesis of diabetic polyneuropathy.
Polyneuropathy is one of the well-known complications of diabetes mellitus.1 The exact cause of the polyneuropathy is not clear despite considerable knowledge of chemical, physiological and histological alterations in diabetic nerves.2 The aetiologic hypothesis of the polyol pathway, initially proposed for galactosaemic and diabetic cataract,3 has been suggested also for diabetic nerve damage.4 With high serum glucose levels, some glucose will escape glycolytic breakdown and instead be metabolised to sorbitol and fructose. Enzymes involved in this process are aldose reductase and sorbitol dehydrogenase. Sorbitol and fructose will accumulate in tissues freely permeable to glucose, like lens and nerve4-6 and this accumulation would then cause osmotic damage to the nerve.7 Indirect evidence for this sequence of events is provided by studies on galactose-fed rats, in which an inverse relationship was found between nerve dulcitol (galactitol) and water content on the one hand and motor conduction velocities on the other hand.8 Inhibition of aldose 
Results
Before treatment the groups of patients were comparable as to age and duration of the diabetes (table  1) . Sex distribution was uneven (table 1) , but did not influence the results. As illustrated by fig I the degree of diabetic control was uniformly moderate throughout the study with no differences for glycosylated haemoglobin (Hb Al), glucosuria and fasting or 2-hour post-prandial glucose between patients on drug and placebo. Body weight was stable or showed only minor fluctuations in all patients except one (on drug), who complained of nausea and lost 5-5 kg during treatment. Diabetes therapy was unchanged throughout the study in all patients except one ID placebo patient. His metabolic control deteriorated more than could be accepted and the insulin dose was slightly increased in the 9th week of the study.
One ID patient on placebo withdrew after about 4 weeks because of an non-specific urticaria (which she had experienced previously). Another ID patient (also on placebo) was excluded after finishing the study, as critical review of his data revealed that he had no convincing objective signs of polyneuropathy (despite some subjective complaints fig 3. Vibration thresholds for ID patients were improved at all sites of measurement, the degree of significance increasing with duration of treatment. Improvement of other sensory modalities was less pronounced, but still statistically significant for temp/foot. NID patients showed a similar pattern, but differences against placebo were less pronounced. The lack of statistical significance for touch/finger and touch/toe, which showed a definite improvement of mean ratio, is explicable by a particularly large variation for this parameter. Figure 3C illustrates the analysis of all the patients. Vibration sense again showed the most improvement with increasing differences versus -0- Analysis of distal latencies from the MCV measurements revealed no difference between the groups of patients on any occasion.
For F-responses a difference between the groups of patients, in favour of Alrestatin, was found for the ulnar nerve at the end of treatment (p < 0-01).
SCV of the sural nerves was often not measurable, despite the use of averaging. There were too few patients in whom SCV could be measured to allow (table 5) . One ID patient complained of epigastric distress, nausea, heartburn and general feeling of illness shortly after having received the dose 8 g/day. He discontinued medication for two days and felt better. Reinstituting treatment caused symptoms to reappear rapidly. At examination there was tenderness over the liver site and elevation of liver transaminase levels were marked (ASAT 4-34 ,ukat/l, ALAT 9 75 jkat/l: normal range < 0-6 ,kat/l for both). A slightly elevated alkaline phosphatase value was also present (5 9 jskat/l; normal range 0-8-4-8 jukat/l). Bilirubin was normal. Treatment was stopped and symptoms gradually disappeared during the first week thereafter. Slightly increased transaminases were still present after 2 and 4 weeks, but normal values were regained at control visit 2 months after discontinuing the drug. fig 4. For this analysis the patient with the pronounced liver reaction and a placebo patient who at three times showed alcoholdependent elevation, were excluded.
Increased urinary albumin was present in 18 patients at the beginning of study (4 ID and 6 NID on the drug, 5 ID and 3 NID on placebo). During treatment dose-related significant elevations of albuminuria values were found in all patients on active treatment, suggesting increases of renal albumin leakage. Values corresponding to pretreatment findings were regained rapidly (one week) after the end of treatment. However, when this unexpected finding was scrutinised, it was found that Alrestatincontaining urine samples did cause dose-related blank peak in the immuno-nephelometric analysis of urinary albumin,20 and it could be shown that the increased values were explained entirely by this laboratory artefact. Thus, no conclusion about influence of Alrestatin on renal albumin excretion can be drawn from the findings. Other laboratory measures mirroring renal function (creatinine, urea, endogenous creatinine clearance) showed no changes.
All other safety evaluations remained unchanged during the study. differences against placebo depended mainly on improvement in treated patients, but partly also on some deterioration among placebo patients ( fig 2B) . This fact does not impair the conclusion, as both real improvement and prevention from further damage to the nerves should be regarded as a beneficial effect of treatment.
The sensory threshold determinations used here are accompanied by pronounced intra-individual variation. 13 
